活動詳細資訊:

The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners across the lifescience and healthcare industry.

Australia is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme. Our Novotech clinical team have almost 20 years’ experience working on 500+ early phase studies, making us an exceptionally experienced local provider within the Australian & New Zealand market and a partner of choice for many international biotech companies.   Dates for RESI : June 5 in person | June 6-7 virtual